| INTANGIBLE ASSETS |
NOTE 5 — INTANGIBLE ASSETS
Intangible assets consisted of the following:
| Intangible Assets | |
March 31,
2026 | | |
December 31,
2025 | |
| Licenses | |
| | | |
| | |
| Non-Exclusive License Agreement | |
$ | 179,821 | | |
$ | 179,821 | |
| Various generic drugs | |
| - | | |
| 736,983 | |
| Four generic drugs (Encore) | |
| - | | |
| 1,308,270 | |
| Needleless Syringe License | |
| 26,060 | | |
| 26,060 | |
| Patents | |
| 48,420 | | |
| 48,420 | |
| Mineral rights and exploratory | |
| 48,416,474 | | |
| - | |
| Total intangible assets, net | |
$ | 48,670,775 | | |
$ | 2,299,554 | |
Intangible assets are as follows:
| | ● | Non-Exclusive License Agreement ($179,821) – On March 5, 2023, the Company signed a Non-Exclusive License Agreement
with Heidelberg University to grant non-exclusive rights to various licenses owned and under development by the university. The licenses
include the use of modified AAV capsid polypeptides for treatment of muscular diseases. The terms include a €50,000 ($56,325) fee
for signing the agreement and €100,000 ($112,650) payment within 60 days of the anniversary of signing the agreement. The Company
will pay €1,000,000 ($1,126,500) for each assignment of a right to a license owned by the university. For new licenses, the Company
will make standard commercial development-based milestone payments for the various stages of license development and regulatory approval.
The Company will make 2% royalty payments by January 31st each year during the term of the agreement for each licensed
product for the proceeding calendar year. The University of Heidelberg license is in good standing. We plan to use this license alongside
other AAV vectors as part of upcoming clinical trials for KLTO-202. The value of the licenses was $179,821 at March 31, 2026 and December
31, 2025, respectively. |
| | ● | Various Generic Drugs ($736,983) - During 2015, the Company acquired two licenses for biosimilar biologic therapies to treat cancer and autoimmune diseases. The value of the licenses was $736,983 at December 31, 2025. For the reporting period as of March 31, 2026, the Company performed an analysis and determined that the various generic drug licenses should be fully impaired and determined the value of these licenses to be $0 at March 31, 2026. |
| | ● | Four Generic Drugs (Encore) ($1,308,270) – On September 12, 2022, the Company acquired four market-approved anti-cancer drugs approved for sale in Germany for $1,308,270. The purchase price represents the fair value of the intangible asset based on the net present value of the projected gross profit to be generated by the licenses. The value of the licenses was $1,308,270 at December 31, 2025. For the reporting period as of March 31, 2026, the Company performed an analysis and determined that the four generic drugs (Encore) licenses should be fully impaired and determined the value of these licenses to be $0 at March 31, 2026. |
| | ● | Needleless Syringe License ($26,060) – On December 1, 2023, the Company signed a license agreement with TransferTech Sherbooke for the rights to develop and commercialize the technology of a “Needleless Syringe.” Under the terms of the agreement, the Company paid a $26,060 upfront fee and royalty fees on the license income. The Company has not commenced developing the technology. The license is in good standing. The Company has worked with Sherbrooke to begin advanced prototyping of the device and has plans to fund continued tech development and selection of drug candidates to pair with the device. The value of the license at March 31, 2026 and December 31, 2025 was $26,060, respectively. | | | ● | Patents ($48,420) – Through its licensing arrangements, the Company acquires the right to patents for Alzheimer, ALS, and other items. Once the patents are declared effective, patents are amortized using the straight-line method over their estimated useful lives or statutory lives, whichever is shorter, and will be reviewed for impairment upon any triggering event that may impact the assets’ ultimate recoverability as prescribed under the guidance related to impairment of long-lived assets. Costs incurred to acquire patents, including legal costs, are also capitalized as long-lived assets and amortized on a straight-line basis with the associated patent. The patent value, which is part of licenses in the accompanying condensed consolidated balance sheet, as of March 31, 2026 and December 31, 2025, was $48,420, respectively. |
| | ● | Exclusive World-wide License Agreement – On January 24, 2022, the Company signed an exclusive, world-wide License Agreement with the University of Barcelona for a cell and/or gene therapy that has shown compelling activity in animal models of human Alzheimer’s disease and amyotrophic lateral sclerosis (“ALS” or “Lou Gehrig’s disease”). The gene therapy will also be applied to age-related diseases and rare (“Orphan”) diseases. Beginning on December 15, 2022, the annual license fee is 10,000 Euros. In addition, the Company will pay a Royalty equal to 3% of net sales of finished products once the license is in use. The UAB license remains in good standing, and the Company plans to use the license for clinical development of its Klotho pipeline, including KLTO-101 and KLTO-202. As of March 31, 2026 and December 31, 2025, the Company owed $0 under the agreement. |
| |
● |
Mineral
rights and early-stage exploration licenses ($48,416,474) – The Company holds mineral rights and early-stage exploration
licenses related to the Skaergaard Project in Greenland. The mineral rights and exploration licenses represent the Company’s
rights to explore, develop, and drill and sample mineral resources within the licensed area. As of March 31, 2026, the Company’s
intangible assets primarily comprise early-stage exploration assets that are not yet ready for their intended use. |
These licenses and patents are not currently in use as the Company
is in pre-revenue stage. Once these licenses are in use, the licenses will be amortized over its useful life.
|